![](/wp-content/uploads/2018/10/sobjPTsRmaFWUV9UlGK8.png)
$599
Biocon/Mylan Glargine CRL; Biocon and Merck Q2 ’18 Earnings
Biocon hosted its CY Q2 ’19 (FY Q1 ’19) earnings call and provided an update on its biosimilar glargine development program including the CRL that was issued in early June 2018. Additionally, Merck hosted its Q2 ’18 earnings call and briefly touched on its diabetes business unit. Below, FENIX provides an overview of the calls and insight on Biocon’s glargine CRL.